Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
Yoshihiko TomitaKo KobayashiGo KimuraMototsugu OyaHirotsugu UemuraHiroyuki NishiyamaMatthew D GalskyFederico NasroulahSandra ColletteEdward BroughtonKeziban Ünsal-KaçmazYukinori KamisukiDean F BajorinPublished in: Japanese journal of clinical oncology (2022)
The efficacy and safety results in the Japanese subgroup were consistent with the overall population of CheckMate 274.